Table 2 NFE2L2 mutations and/or amplification occurring in patients with the proportion of nuclear NRF2 expression >20% and/or nuclear NRF2 IHC score >20.

From: High expression of nuclear NRF2 combined with NFE2L2 alterations predicts poor prognosis in esophageal squamous cell carcinoma patients

Patient no.

Alteration(s)

P20

NFE2L2 amp (CN = 4.4)

P21

NFE2L2 p.R34Q

P50

NFE2L2 p.V32G

P61

NFE2L2 p.I20N

NFE2L2 amp (CN = 3.0)

KEAP1 p.R470H

P67

NFE2L2 p.R34Q

P68

NFE2L2 p.T80_E82delinsI

P80

NFE2L2 amp (CN = 3.0)

KEAP1 p.R272C

P87

NFE2L2 amp (CN = 4.8)

P88

NFE2L2 p.R34P

P98

NFE2L2 p.V32del

P102

NFE2L2 p.I28T

P114

NFE2L2 p.R34Q

NFE2L2 p.E377K

P116

NFE2L2 amp (CN = 3.5)

KEAP1 p.D294Y

P126

NFE2L2 p.F37L

P128

NFE2L2 p.F37S

  1. NRF2 (NFE2L2) Nuclear factor erythroid-2 related factor-2, IHC Immunohistochemistry, amp Amplification, del Deletion, delins Deletion and insertion, CN Copy number, KEAP1 Kelch-like ECH-associated protein 1.
Back to article page